» Articles » PMID: 39737785

Spatial Proteomic Differences in Chronic Traumatic Encephalopathy, Alzheimer's Disease, and Primary Age-related Tauopathy Hippocampi

Abstract

Introduction: Alzheimer's disease (AD), primary age-related tauopathy (PART), and chronic traumatic encephalopathy (CTE) all feature hyperphosphorylated tau (p-tau)-immunoreactive neurofibrillary degeneration, but differ in neuroanatomical distribution and progression of neurofibrillary degeneration and amyloid beta (Aβ) deposition.

Methods: We used Nanostring GeoMx Digital Spatial Profiling to compare the expression of 70 proteins in neurofibrillary tangle (NFT)-bearing and non-NFT-bearing neurons in hippocampal CA1, CA2, and CA4 subregions and entorhinal cortex of cases with autopsy-confirmed AD (n = 8), PART (n = 7), and CTE (n = 5).

Results: There were numerous subregion-specific differences related to Aβ processing, autophagy/proteostasis, inflammation, gliosis, oxidative stress, neuronal/synaptic integrity, and p-tau epitopes among these different disorders.

Discussion: These results suggest that there are subregion-specific proteomic differences among the neurons of these disorders, which appear to be influenced to a large degree by the presence of hippocampal Aβ. These proteomic differences may play a role in the differing hippocampal p-tau distribution and pathogenesis of these disorders.

Highlights: Alzheimer's disease neuropathologic change (ADNC), possible primary age-related tauopathy (PART), definite PART, and chronic traumatic encephalopathy (CTE) can be differentiated based on the proteomic composition of their neurofibrillary tangle (NFT)- and non-NFT-bearing neurons. The proteome of these NFT- and non-NFT-bearing neurons is largely correlated with the presence or absence of amyloid beta (Aβ). Neurons in CTE and definite PART (Aβ-independent pathologies) share numerous proteomic similarities that distinguish them from ADNC and possible PART (Aβ-positive pathologies).

Citing Articles

Spatial proteomic differences in chronic traumatic encephalopathy, Alzheimer's disease, and primary age-related tauopathy hippocampi.

Richardson T, Orr M, Orr T, Rohde S, Ehrenberg A, Thorn E Alzheimers Dement. 2024; 21(2):e14487.

PMID: 39737785 PMC: 11848160. DOI: 10.1002/alz.14487.

References
1.
Huttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S . Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018; 6(1):108. PMC: 6194687. DOI: 10.1186/s40478-018-0612-3. View

2.
. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7(2):e105-e125. PMC: 8810394. DOI: 10.1016/S2468-2667(21)00249-8. View

3.
Daneshvar D, Nair E, Baucom Z, Rasch A, Abdolmohammadi B, Uretsky M . Leveraging football accelerometer data to quantify associations between repetitive head impacts and chronic traumatic encephalopathy in males. Nat Commun. 2023; 14(1):3470. PMC: 10281995. DOI: 10.1038/s41467-023-39183-0. View

4.
Braak H, Thal D, Ghebremedhin E, Del Tredici K . Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70(11):960-9. DOI: 10.1097/NEN.0b013e318232a379. View

5.
Jellinger K . Different patterns of hippocampal tau pathology in Alzheimer's disease and PART. Acta Neuropathol. 2018; 136(5):811-813. DOI: 10.1007/s00401-018-1894-z. View